1月19日，中国证监会官网披露境外发行上市备案补充材料要求公示，要求诚益生物补充说明关于股权 架构搭建及返程并购的合规性、股本情况、境内运营实体等三大事项，并请律师核查并出具明确的法律 意见。 2025年10月8日，诚益生物向港交所递交上市申请材料。2023年、2024年以及2025年上半年，公司分别 实现净利润-5222.7万美元、1.39亿美元以及-2011.3万美元。诚益生物在上市申请材料中表示，公司仅有 一名客户，即阿斯利康，也是公司的股东之一。 仅有一名客户 2025年10月8日，诚益生物向港交所递交上市申请材料。 诚益生物创立于2018年，是一家处于临床阶段的全球性生物技术公司，致力于探索及开发新一代口服小 分子药物，以解决全球心血管代谢疾病及炎症性疾病领域尚未满足的重大医疗需求。公司开发了 TRANDD平台，以支持探索及研发的完整工作流程，从而使公司能够在启动项目后短短四年内，将三 种不同的候选药物推进临床开发。 2023年、2024年以及2025年上半年，公司分别实现营业收入3605.9万美元、2.21亿美元以及55.7万美 元，净利润约为-5222.7万美元、1.39亿美元以及-2011.3 ...

Core Insights - The IPO market is experiencing significant activity, particularly in the Hong Kong stock market, with a notable number of companies filing for listings, including many dual-listed A+H companies [2][17] - New listings have shown remarkable performance, with companies like Aomisen and Jinye International Group achieving substantial first-day gains and record oversubscription rates [6][8][9][10] Recent Approvals - Guanghetong has received approval for its listing on the Hong Kong Stock Exchange, with projected revenues increasing from 5.203 billion yuan in 2022 to 6.971 billion yuan in 2024 [3] - Tongrentang Medical has also passed its hearing, reporting revenues of 910 million yuan in 2022, with a projected increase to 1.175 billion yuan in 2024 [4] - Haixi New Drug has been approved for listing, with revenues expected to grow from 212.5 million yuan in 2022 to 466.7 million yuan in 2024 [5] New Listings - Aomisen debuted on the Beijing Stock Exchange with a first-day surge of 349.8%, achieving a market capitalization of 2.97 billion yuan [6] - Jinye International Group listed on the Hong Kong Stock Exchange with a staggering oversubscription rate of 11,464.7 times, closing up 330% on its first day [8] - Zhida Technology's IPO was marked by a 192.14% increase on its first trading day, establishing it as a leader in the home electric vehicle charging solutions market [9] - Changfeng Pharmaceutical's shares opened at 48 HKD, a 225.42% increase, with a revenue CAGR of 31.9% projected from 2022 to 2024 [10] Recent Filings - Lantu Motors has filed for a listing on the Hong Kong Stock Exchange, showing significant revenue growth from 6.052 billion yuan in 2022 to 19.361 billion yuan in 2024 [11] - Chengyi Biotechnology has initiated its IPO process, focusing on developing new oral small molecule drugs for cardiovascular and inflammatory diseases [12] - Senyi Medical has filed for an IPO, recognized as a leading AI medical solution provider in China [13] - Annuo Youda has submitted its prospectus for an IPO, specializing in molecular diagnostics and IVD medical devices [14] - WeDoctor is making another attempt to list on the Hong Kong Stock Exchange after previous unsuccessful attempts [15] Market Trends - In the first three quarters of 2025, Chinese companies have shown increased IPO activity, with 161 listings, a 25.8% year-on-year increase, and a total fundraising amount of approximately 193.73 billion yuan [17] - The Hong Kong market saw 60 Chinese companies listed in the first three quarters, reflecting a 53.8% increase compared to the previous year [18]